mRNA Vaccines in the COVID-19 Pandemic and Beyond

Annual Review of Medicine - Tập 73 Số 1 - Trang 17-39 - 2022
Michael J. Hogan1, Norbert Pardi2
1Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA;
2Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA

Tóm tắt

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), emerged in China in December 2019 and quickly spread around the globe, killing more than 4 million people and causing a severe economic crisis. This extraordinary situation prompted entities in government, industry, and academia to work together at unprecedented speed to develop safe and effective vaccines. Indeed, vaccines of multiple types have been generated in record time, and many have been evaluated in clinical trials. Of these, messenger RNA (mRNA) vaccines have emerged as lead candidates due to their speed of development and high degree of safety and efficacy. To date, two mRNA vaccines have received approval for human use, providing proof of the feasibility of this next-generation vaccine modality. This review gives a detailed overview about the types of mRNA vaccines developed for SARS-CoV-2, discusses and compares preclinical and clinical data, gives a mechanistic overview about immune responses generated by mRNA vaccination, and speculates on the challenges and promising future of this emergent vaccine platform.

Từ khóa


Tài liệu tham khảo

10.1038/s41586-020-2798-3

10.1016/S0140-6736(21)00306-8

10.1038/nrd.2017.243

10.1016/j.coi.2020.01.008

10.1056/NEJMoa2034577

10.1056/NEJMoa2035389

10.1056/NEJMoa2101765

10.1056/NEJMoa2110345

10.1038/s41577-020-00480-0

10.1073/pnas.1707304114

Alameh MG, 2020, Curr. Top. Microbiol. Immunol.

Moderna, 2021, Moderna reports second quarter fiscal year 2021 financial results and provides business updates

10.1016/S1473-3099(21)00677-0

FDA, 2021, FDA approves first COVID-19 vaccine. News Release

10.1038/s41586-020-2639-4

10.1038/s41586-020-2814-7

10.1056/NEJMoa2027906

10.1038/s41586-020-2622-0

10.1056/NEJMoa2024671

10.1038/s41564-020-00789-5

10.1056/NEJMoa2022483

10.1056/NEJMoa2028436

10.1016/j.xcrm.2021.100355

Moderna, 2021, Moderna provides clinical and supply updates on COVID-19 vaccine program ahead of 2nd annual Vaccines Day

10.1056/NEJMc2103916

10.1126/science.abj4176

Basta NE, Moodie EMM (McGill Univ. COVID-19 Vaccine Tracker Team). 2020. COVID-19 vaccine development and approvals tracker. Accessed Sep. 26, 2021. https://covid19.trackvaccines.org/agency/who

10.1056/NEJMc2102017

10.1126/science.abg6105

10.1038/s41586-021-03653-6

10.1038/s41586-021-03275-y

Pfizer, 2021, Second quarter 2021 earnings teleconference

10.1038/s41586-021-03324-6

10.1001/jama.2021.15125

10.15585/mmwr.mm7038e1

10.1038/mt.2015.103

10.1038/s41541-021-00311-w

Rauch S, Gooch K, Hall Y, et al. 2021. mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection. bioRxiv 424138. https://doi.org/10.1101/2020.12.23.424138

Kremsner P, Mann P, Bosch J, et al. 2021. Phase 1 assessment of the safety and immunogenicity of an mRNA–lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers. medRxiv 20228551. https://doi.org/10.1101/2020.11.09.20228551

10.1016/j.cell.2020.07.024

10.1038/s41541-021-00324-5

Sanofi Pasteur, 2021, Sanofi and Translate Bio initiate phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate

10.1038/s41467-020-17409-9

10.1016/j.ymthe.2021.04.001

Arcturus Therapeutics, 2020, Arcturus Therapeutics received approval from Singapore Health Sciences Authority to proceed with phase 2 study of ARCT-021 (LUNAR-COV19) vaccine candidate and provides new and updated clinical and preclinical data

10.1038/s41591-021-01377-8

Gilbert PB, Montefiori DC, McDermott A, et al. 2021. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy trial. medRxiv 2021.08.09.21261290. https://doi.org/10.1101/2021.08.09.21261290

10.1126/science.abe2402

10.1038/s41586-020-03041-6

10.1126/science.abe3354

10.1016/j.immuni.2020.07.019

10.1038/nature21428

10.1084/jem.20171450

10.1016/j.ymthe.2017.03.035

10.1038/s41467-018-05482-0

10.1016/j.cell.2017.02.017

10.3389/fimmu.2017.01539

10.1016/j.immuni.2020.11.009

10.3390/vaccines9020147

10.1016/j.immuni.2005.06.008

10.1093/nar/gkr586

10.1093/nar/gkq347

10.1038/mt.2008.200

10.1038/mt.2012.7

10.1016/j.jconrel.2015.08.051

10.1073/pnas.1606050113

10.1146/annurev-immunol-041015-055605

10.1093/nar/gkr695

10.1016/j.omtn.2019.02.018

10.1016/j.jconrel.2015.08.007

10.3390/vaccines9010065

10.1016/j.omtn.2019.01.013

10.1016/j.vaccine.2015.10.132

10.1038/srep34215

10.1002/eji.200737998

10.1016/j.nano.2013.12.003

10.1038/ni.2350

Ndeupen S, Qin Z, Jacobsen S, Estanbouli H, et al. 2021. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. bioRxiv 430128. https://doi.org/10.1101/2021.03.04.430128

10.1038/s41541-017-0032-6

10.1016/j.ymthe.2017.08.006

Thompson MG, 2021, Morb. Mortal. Wkly. Rep., 70, 495, 10.15585/mmwr.mm7013e3

Puranik A, Lenehan PJ, Silvert E, et al. 2021. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv 2021.08.06.21261707. https://doi.org/10.1101/2021.08.06.21261707

Goldberg Y, Mandel M, Bar-On YM, et al. 2021. Waning immunity of the BNT162b2 vaccine: a nationwide study from Israel. medRxiv 2021.08.24.21262423. https://doi.org/10.1101/2021.08.24.21262423

Antonelli M, 2021, Lancet Infect. Dis.

10.1038/s41586-021-03777-9

10.1038/s41586-021-03944-y

10.1056/NEJMoa2108891

10.1101/2021.08.18.21262237

Wu K, Choi A, Koch M, et al. 2021. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. bioRxiv 439482. https://doi.org/10.1101/2021.04.13.439482

Moderna, 2021, Moderna announces significant advances across industry-leading mRNA portfolio at 2021 R&D Day

10.1001/jama.2021.1967

10.1001/jama.2021.15072

10.1080/14686996.2019.1627174

10.15585/mmwr.mm7027e2

10.1056/NEJMc2103916

10.1007/s10654-021-00728-6

10.1136/bmj.m3320

10.1056/NEJMoa2107456

Moderna, 2021, Moderna announces TeenCOVE study of its COVID-19 vaccine in adolescents meets primary endpoint and plans to submit data to regulators in early June

Pfizer, 2021, Pfizer and BioNTech announce positive topline results from pivotal trial of Covid-19 vaccine in children 5 to 11 years

Gray KJ, 2021, Am. J. Obstet. Gynecol., 225, 303.e1–e17

10.1056/NEJMoa2104983

Bergman P, Blennow O, Hansson L, et al. 2021. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. medRxiv 2021.09.07.21263206. https://doi.org/10.1101/2021.09.07.21263206

10.1001/jama.2021.1865

HHS (Dep. Health Hum. Serv.), 2021, Biden Administration purchases additional doses of COVID-19 vaccines from Pfizer and Moderna

Pfizer, 2021, Pfizer reports fourth-quarter and full-year 2020 results and releases 5-year pipeline metrics

Duke Global Health Innov. Cent. 2021. Launch and scale speedometer. Duke Univ. Accessed Apr. 2. https://launchandscalefaster.org/covid-19

WHO, 2021, Joint COVAX statement on supply forecast for 2021 and early 2022

10.1056/NEJMc2113468

Moderna, 2021, Moderna announces submission of initial data to U.S. FDA for its COVID-19 vaccine booster

10.1056/NEJMoa2114255

WHO, 2021, WHO Director-General's opening remarks at the media briefing on COVID-19—8 September 2021

10.1016/j.ijpharm.2021.120586

FDA (Food Drug Adm.), 2021, Coronavirus (COVID-19) update: FDA allows more flexible storage, transportation conditions for Pfizer-BioNTech COVID-19 vaccine

Moderna, 2021, First participants dosed in phase 1 study evaluating mRNA-1283, Moderna's next generation COVID-19 vaccine

10.1126/science.abd0826

10.1016/j.medj.2020.11.004

10.1038/ncomms14630

Thông tin
Thông tin xuất bản

Annual Review of Medicine

Tập 73 Số 1

17-39

Thông tin tác giả